October 07, 2011
Not intended for U.S. and UK media: Secondary Prevention of Acute Coronary Syndrome:

Phase III Study of Bayer's Rivaroxaban in Patients with Acute Coronary Syndrome Accepted for Presentation as Late Breaker at AHA Scientific Sessions 2011

Full results of Phase III ATLAS ACS 2 TIMI 51 clinical trial to be presented on November 13, 2011

Berlin, Germany, October 7, 2011 - Bayer HealthCare AG announced today that the results from the Phase III ATLAS ACS 2 TIMI 51 clinical trial of rivaroxaban (Xarelto®) have been accepted for presentation in the Late Breaking Clinical Trials Session of the American Heart Association's Scientific Sessions 2011. The results will be presented by C. Michael Gibson, M.S., M.D., TIMI Study Group, Boston, MA, on Sunday, November 13, from 5:13 PM - 5:23 PM (ET).

About Rivaroxaban (Xarelto®)
Rivaroxaban is an oral anticoagulant that was discovered in Bayer HealthCare's Wuppertal laboratories in Germany, and is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. It has a rapid onset of action with a predictable dose response and high bioavailability, no requirement for coagulation monitoring, and a limited potential for food and drug interactions.

Xarelto® is marketed for VTE prevention in adult patients following elective hip or knee replacement surgery, and it is the only oral anticoagulant that has consistently demonstrated superior efficacy over enoxaparin for this indication. To date, Xarelto® is approved in more than 110 countries worldwide and has been successfully launched in more than 85 countries by Bayer HealthCare in this indication. In the U.S., where Xarelto® has been successfully launched in its first indication in July 2011, Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company) holds marketing rights. The Bayer HealthCare sales force is supporting Janssen Pharmaceuticals, Inc. in designated hospital accounts.

The extensive clinical trial program supporting rivaroxaban makes it the most studied and widely published oral, direct Factor Xa inhibitor. The studies, reported and ongoing, involve over 75,000 patients for the prevention and treatment of venous and arterial thromboembolic (VAT) disorders across a broad range of acute and chronic conditions, including stroke prevention in patients with atrial fibrillation, VTE treatment, and the secondary prevention of Acute Coronary Syndrome.

To learn more about thrombosis, please visit www.thrombosisadviser.com.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Find more information at www.bayerpharma.com.

Forward-looking statements<br/>This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.